Julie A. Krueger

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice

Helen B. Hartman, Stephen J. Gardell, Chris Petucci et al. · Journal of Lipid Research · 2009 · 150 citations · Full text

Vascular Disease, Immunology, Farnesoid X Receptor +22

Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines

Christopher S. Burgey, Kyle A. Robinson, Terry A. Lyle et al. · Journal of Medicinal Chemistry · 2003 · 120 citations · Full text

Pharmaceutical Science, Oral Bioavailability, Pharmacotherapy +18

Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position

Thomas J. Tucker, Stephen F. Brady, William C. Lumma et al. · Journal of Medicinal Chemistry · 1998 · 105 citations · Full text

Pharmaceutical Science, Bioorganic Chemistry, Pharmacotherapy +18

A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site

Mary Ann Hardwicke, Alan R. Rendina, Shawn P. Williams et al. · Nature Chemical Biology · 2014 · 103 citations · Full text

Metabolic Syndrome, Lipid Synthesis, Biochemistry +9

Discovery and Evaluation of Potent P₁ Aryl Heterocycle-Based Thrombin Inhibitors

Mary Beth Young, James C. Barrow, Kristen L. Glass et al. · Journal of Medicinal Chemistry · 2004 · 93 citations · Full text

Molecular Docking, Combinatorial Chemistry, Medicinal Chemistry +15